Table 3.
Patient characteristics at baseline classified by constipation
| Items | Without constipation (n = 20) | With constipation (n = 20) | P‐value |
|---|---|---|---|
| Gender | |||
| Male | 15 (75%) | 12 (60%) | 0.501 |
| Female | 5 (25%) | 8 (40%) | |
| ECOG‐PS | |||
| 0–1 | 20 (100%) | 10 (50%) | 0.0004 |
| 2–4 | 0 (0%) | 10 (50%) | |
| Histology | |||
| Adenocarcinoma | 13 (65%) | 7 (35%) | 0.301 |
| Squamous cell carcinoma | 4 (20%) | 8 (40%) | |
| Other | 3 (15%) | 5 (25%) | |
| Smoking status | |||
| Never smoker | 4 (20%) | 7 (35%) | 0.48 |
| Smoker | 16 (80%) | 13 (65%) | |
| Staging | |||
| Stage IV | 17 (85%) | 16 (80%) | 1 |
| Postoperative recurrence | 3 (15%) | 4 (20%) | |
| EGFR mutations | |||
| Positive | 5 (25%) | 2 (10%) | 0.407 |
| Negative | 15 (75%) | 18 (90%) | |
| PD‐L1 TPS | |||
| ≥50% | 6 (30%) | 6 (30%) | 0.297 |
| 1–49% | 4 (20%) | 2 (10%) | |
| <1% | 1 (5%) | 4 (20%) | |
| Not evaluated | 9 (45%) | 8 (40%) | |
| Metastasis | |||
| Liver metastasis | 1 (5%) | 4 (20%) | 0.342 |
| Brain metastasis | 8 (40%) | 6 (30%) | 0.741 |
| Medication history | |||
| Opioid | 2 (10%) | 6 (30%) | 0.235 |
ECOG‐PS, Eastern Cooperative Oncology Group Performance Status; EGFR, epidermal growth factor receptor; PD‐L1, programmed death ligand 1; TPS, tumor proportion score.